KRYS News and Press, Krystal Biotech Inc. From 09/29/22

PITTSBURGH, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, announced today that the Company will participate in the Chardan’s 6 th Annual Genetic Medicines Conference in New York...

Summary Baker Brothers’ 13F portfolio value increased from $17.40B to $17.63B this quarter. Global Blood Therapeutics, Horizon Therapeutics, and Kymera Therapeutics were increased during the quarter. The top three positions are Seagen, Incyte Corporation, and BeiGene, a...

An expert panel of the EU drug regulator has issued a positive opinion on the Pediatric Investigation Plan (PIP) for gene therapy B-VEC, allowing the developer Krystal Biotech, Inc. ( NASDAQ: KRYS ) to file a marketing application targeting a rare skin disorder. The compan...

• Company on track to submit European marketing application in Q4 2022 • No additional studies required PITTSBURGH, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, an...

When fear rules the markets, investors usually have a hard time seeing the long-term benefits of stock investing. Even share prices of companies with potentially solid long-term prospects remain depressed. In such an environment it does become difficult to identify the real winners. The...

PITTSBURGH, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, announced today that the Company will participate in the H.C. Wainwright 24 th Annual Global Investment Conference in New York...

Krystal Biotech ( NASDAQ: KRYS ) on Thursday said the U.S. FDA had accepted its biologics license application for its gene therapy B-VEC for the treatment of dystrophic epidermolysis bullosa (DEB). DEB  is a genetic skin disorder affecting skin and nails tha...

FDA granted Priority Review designation PDUFA target action date is February 17, 2023 FDA stated that it is not currently planning to hold an advisory committee meeting PITTSBURGH, Aug. 18, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Companyȁ...

Krystal Bio (KRYS) has performed well in the last two months that I have had it. Its B-VEC looks highly approvable. With Amryt's CRL, the competitive gap has widened in favor of Krystal. Krystal Biotech ( KRYS ) is up hugely since I first covered it earlier this year...

Krystal Biotech press release ( NASDAQ: KRYS ): Q2 GAAP EPS of -$1.10 misses by $0.07 . Strong balance sheet, closing the quarter with $438.5 million in cash, cash equivalents and investments. For further details see: Krystal Biotech GAAP EPS of -$1.10 misses...